Erasca, Inc.ERAS

Erasca, Inc. filed a Form 144 on July 21, 2026, disclosing that Erasca Foundation intends to sell up to 1,800,000 shares of the company’s common stock. The foundation’s designated representative checked the “image candidate” radio button on the SEC’s template, a small but telling ritual that turns a regulatory checkbox into a visual cue about who’s still willing to put capital at risk. (source: ERAS 144 (2026-07-21), https://www.sec.gov/Archives/edgar/data/1761918/000162828026048993/xsl144X01/primary_doc.xml)

Erasca calls itself a clinical-stage precision oncology company aiming to crack the genetic code behind RAS-driven cancers with a “purpose-built” pipeline of molecular glues and inhibitors. In plain language, the firm is betting its future on ERAS-0015 (a pan-RAS molecular glue), ERAS-4001 (a pan-KRAS inhibitor), and ERAS-12 (an EGFR biparatopic still in discovery). The company’s latest 10-Q, filed for the quarter ending March 31 2026, does not contain a revenue line, which is the financial equivalent of turning up to a beauty pageant without a swimsuit round. (source: ERAS 424B5 (2026-07-14), https://www.sec.gov/Archives/edgar/data/1761918/000119312526303352/d116467d424b5.htm)

What the filings do show is a company haemorrhaging cash. Erasca reported a net loss attributable to the parent of $183.4 million, an operating loss of $187.9 million, and negative operating cash flow of $27.4 million for Q1 2026. The balance sheet still looks tidy enough-$461.2 million in assets against $67.7 million in liabilities-but only if you ignore the $47.3 million in cash and equivalents and the fact that diluted EPS came in at negative sixty cents on 304.3 million shares. Capex was a genteel $36,000, the sort of figure that suggests the firm’s idea of heavy industry is upgrading the office printer. (source: ERAS 10-Q (period ending 2026-03-31), https://www.sec.gov/Archives/edgar/data/1761918/000119312526303352/d116467d424b5.htm)

For investors hunting for a chart context, Erasca trades on the NASDAQ under the symbol ERAS. The company’s S-3ASR shelf registration, filed on July 13 2026, is broad enough to fund an entire oncology department, yet the hard question remains: when will the pipeline’s preclinical chatter translate into actual revenue? Until then, the stock’s price action will continue to dance to the rhythm of clinical timelines and dilution cadence rather than any hard earnings beat. (source: ERAS S-3ASR (2026-07-13), https://www.sec.gov/Archives/edgar/data/1761918/000119312526303352/d133579ds3asr.htm)

On July 13 2026, Erasca issued an 8-K announcing updated preliminary Phase 1 data for ERAS-0015 in patients with RAS-mutant solid tumours. The word “updated” is the biotech equivalent of a polite knock on the door of a breakthrough; it signals progress while stopping short of a full-throated victory lap. The same filing also reminds readers that Erasca’s pipeline includes two clinical-stage programmes and one discovery-stage programme, a construction kit that looks impressive until you notice there’s no revenue line in the 10-Q to prove the kit has left the garage. (source: ERAS 8-K (2026-07-13), https://www.sec.gov/Archives/edgar/data/1761918/000119312526302045/d54726d8k.htm)

The company’s July 14 2026 prospectus supplements (424B5 forms) repeatedly state the same pipeline mantra-ERAS-0015, ERAS-4001, ERAS-12-yet provide no revenue bridge, no cash runway bridge, and no clarity on when the first product might reach the market. In the absence of hard numbers, the filings read less like a business plan and more like a pitch slide deck that forgot to attach the appendix of actual sales. (source: ERAS 424B5 (2026-07-14), https://www.sec.gov/Archives/edgar/data/1761918/000119312526303352/d116467d424b5.htm)

Erasca’s SEC submissions page shows a flurry of filings in the past fortnight, including a shelf registration, prospectus supplements, and the Form 144. Taken together, the filing trail paints the picture of a company that is actively raising capital and positioning itself for the long game of precision oncology. Whether the capital raised will outrun the burn rate, and whether the pipeline will deliver before the cash runs dry, remains the billion-dollar question the filings themselves cannot answer. (source: ERAS SEC submissions JSON (2026-07-25), https://data.sec.gov/submissions/CIK0001761918.json)